You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
116 search results for: symposium
expert video
ERS 2023 | Adult Asthma Symposium: Mini Debate
Pulmonology
Prof. Ian Pavord moderates a debate between Prof. Vibeke Backer and Dr. Francesca Puggioni about what a patient's lung function should be in order to be defined as achieving clinical remission in adult asthma.
ERS 2023 | Adult Asthma Symposium: Panel Discussion
Pulmonology
Profs. Ian Pavord and Vibeke Backer and Dr. Francesca Puggioni and audience members share their views on the proposed framework for clinical remission in severe asthma.
The Association Between Epidermal Barrier Dysfunction and S. aureus Colonization in Atopic Dermatitis
Dermatology
Dr. Lisa Beck highlights the association between epidermal barrier dysfunction and S. aureus colonization in her talk at the ISDS 2023 ADVENT symposium.
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP
Dermatology
This full video presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida features Dr. Eric Simpson, Dr. Shawn Kwatra, Dr. Jason Hawkes and Dr. Victoria Werth. The faculty present the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).
Role of Type 2 Inflammation in Skin Barrier Disruption and Itch
Dermatology
In this highlight video from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Christine Bangert discusses how type 2 inflammation contributes to epidermal barrier dysfunction and chronic itch in AD
In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Lisa Weibel discusses how type 2 inflammation contributes to epidermal barrier dysfunction and AD signs and symptoms.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.